VITA 34 Past Earnings Performance
Past criteria checks 0/6
VITA 34's earnings have been declining at an average annual rate of -51.5%, while the Healthcare industry saw earnings growing at 10.6% annually. Revenues have been growing at an average rate of 35.4% per year.
Key information
-51.5%
Earnings growth rate
-49.8%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | 35.4% |
| Return on equity | -0.8% |
| Net Margin | -0.1% |
| Next Earnings Update | 25 Nov 2024 |
Recent past performance updates
Recent updates
Why We're Not Concerned About VITA 34 AG's (ETR:V3V) Share Price
Apr 04
Revenues Tell The Story For VITA 34 AG (ETR:V3V) As Its Stock Soars 26%
Dec 24Is VITA 34 (ETR:V3V) Using Too Much Debt?
Nov 23Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?
Jul 15Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?
Feb 17Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?
Apr 08VITA 34 AG's (ETR:V3V) CEO Compensation Looks Acceptable To Us And Here's Why
Dec 07Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?
May 12Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their Forecasts
Apr 03VITA 34 AG's (ETR:V3V) Intrinsic Value Is Potentially 56% Above Its Share Price
Mar 25Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?
Mar 10Here's Why VITA 34 (ETR:V3V) Can Manage Its Debt Responsibly
Feb 22Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?
Feb 05Can Mixed Financials Have A Negative Impact on VITA 34 AG's 's (ETR:V3V) Current Price Momentum?
Jan 18Did You Participate In Any Of VITA 34's (ETR:V3V) Fantastic 201% Return ?
Jan 02How Is VITA 34's (ETR:V3V) CEO Compensated?
Dec 18Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?
Dec 01
Revenue & Expenses Breakdown
How VITA 34 makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 79 | 0 | 33 | 0 |
| 31 Mar 24 | 78 | 0 | 33 | 0 |
| 31 Dec 23 | 77 | -2 | 32 | 0 |
| 30 Sep 23 | 75 | -25 | 33 | 0 |
| 30 Jun 23 | 73 | -24 | 32 | 0 |
| 31 Mar 23 | 71 | -27 | 32 | 0 |
| 31 Dec 22 | 69 | -27 | 32 | 0 |
| 30 Sep 22 | 63 | -12 | 29 | 0 |
| 30 Jun 22 | 50 | -11 | 24 | 0 |
| 31 Mar 22 | 39 | -6 | 18 | 0 |
| 31 Dec 21 | 28 | -4 | 13 | 0 |
| 30 Sep 21 | 21 | 0 | 10 | 0 |
| 30 Jun 21 | 21 | 0 | 9 | 0 |
| 31 Mar 21 | 20 | 1 | 9 | 0 |
| 31 Dec 20 | 20 | 1 | 9 | 0 |
| 30 Sep 20 | 20 | 1 | 9 | 0 |
| 30 Jun 20 | 20 | 1 | 9 | 0 |
| 31 Mar 20 | 20 | 1 | 10 | 0 |
| 31 Dec 19 | 20 | 1 | 10 | 0 |
| 30 Sep 19 | 20 | 1 | 9 | 0 |
| 30 Jun 19 | 20 | 1 | 9 | 0 |
| 31 Mar 19 | 20 | 1 | 10 | 0 |
| 31 Dec 18 | 20 | 1 | 10 | 0 |
| 30 Sep 18 | 21 | 2 | 10 | 0 |
| 30 Jun 18 | 21 | 1 | 11 | 0 |
| 31 Mar 18 | 20 | 0 | 11 | 0 |
| 31 Dec 17 | 19 | 0 | 10 | 0 |
| 30 Sep 17 | 18 | -1 | 10 | 0 |
| 30 Jun 17 | 16 | -1 | 10 | 0 |
| 31 Mar 17 | 17 | 1 | 9 | 0 |
| 31 Dec 16 | 16 | 0 | 9 | 0 |
| 30 Sep 16 | 16 | 2 | 10 | 0 |
| 30 Jun 16 | 16 | 2 | 9 | 0 |
| 31 Mar 16 | 15 | 2 | 9 | 0 |
| 31 Dec 15 | 14 | 2 | 9 | 0 |
| 30 Sep 15 | 14 | 1 | 8 | 0 |
| 30 Jun 15 | 14 | 1 | 8 | 0 |
| 31 Mar 15 | 14 | 1 | 8 | 0 |
| 31 Dec 14 | 14 | 1 | 8 | 0 |
| 30 Sep 14 | 14 | 1 | 8 | 0 |
| 30 Jun 14 | 13 | 1 | 8 | 0 |
| 31 Mar 14 | 14 | 1 | 8 | 0 |
| 31 Dec 13 | 14 | 1 | 8 | 0 |
Quality Earnings: V3V is currently unprofitable.
Growing Profit Margin: V3V is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: V3V is unprofitable, and losses have increased over the past 5 years at a rate of 51.5% per year.
Accelerating Growth: Unable to compare V3V's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: V3V is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (40.5%).
Return on Equity
High ROE: V3V has a negative Return on Equity (-0.8%), as it is currently unprofitable.